This clinical trial is focused on studying a condition known as transfusion-dependent thalassemia, which includes both α-thalassemia and β-thalassemia. These are blood disorders that require regular blood transfusions. The trial will test a new treatment called SP-420, which is taken as a capsule. The purpose of the study is to find the right dose of SP-420 and to see how well it works in removing excess iron from the body over a period of 24 weeks.

Participants in the study will take SP-420 orally, which means they will swallow the capsules. The study will last for up to 48 weeks, during which the amount of iron in the body will be measured at different times. This will help researchers understand how much iron is removed by SP-420. The study will also monitor changes in the amount of iron in the liver using a method called magnetic resonance imaging (MRI), which is a type of scan that provides detailed images of the inside of the body.

Throughout the study, researchers will keep track of any side effects that participants might experience. The main goal is to determine how effective SP-420 is at reducing iron levels in people with transfusion-dependent thalassemia, while also ensuring the treatment is safe. Participants will be closely monitored by healthcare professionals to ensure their well-being during the trial.